dr. brufsky discusses resistance to her2-targeted therapies
Published 7 years ago • 127 plays • Length 2:33
Download video MP4
Download video MP3
Similar videos
-
1:13
dr. hamilton on overcoming resistance to her2-targeted therapy in breast cancer
-
1:22
dr. brufsky on trastuzumab and eribulin for her2 metastatic breast cancer
-
1:06
dr. brufsky on challenges in breast cancer
-
2:39
adam brufsky, md, phd, describes the treatment landscape of her2 metastatic breast cancer
-
1:49
dr. brufsky on multiparametric genomic assays in breast cancer
-
1:38
dr. brufsky on the results of a study of trastuzumab and eribulin for her2 mbc
-
3:21
adam brufsky, md, phd, considers the investigation of poziotinib in her2 metastatic breast cancer
-
1:04
adam brufsky, md, phd: expectations of therapy
-
5:28
her2-targeted therapy in early breast cancer
-
2:47
adam brufsky, md, phd: clinical trial data supporting these choices
-
4:20
pik3ca mutations in her2-positive breast cancer
-
1:10
adam brufsky, md, phd: choices of therapy
-
1:41
dr. brufsky on implementing pertuzumab in her2 breast cancer
-
1:44
adam brufsky, md, phd: choices of therapy in breast cancer
-
0:49
adam brufsky, md, phd: considerations for different therapies in breast cancer
-
8:40
first-line treatment of her2-positive metastatic breast cancer
-
1:05
dr. tripathy on markers of resistance in breast cancer
-
8:18
esr mutations and resistance to endocrine therapy
-
1:07
dr. brufsky on challenges facing biosimilars in breast cancer
Clip.africa.com - Privacy-policy